{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008811","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.375385+00:00","generated_at":"2026-06-15T09:37:10.923573+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Olema Pharma Q1 net loss $28.3M, cash $186M; Phase 3 trial of OP-1250 planned H2 2023","bullets":["Cash, cash equivalents and marketable securities of $186.0M as of March 31, 2023, expected to fund operations into 2025.","Net loss for Q1 2023 was $28.3M, compared to $23.0M in Q1 2022, with R&D expenses rising to $22.8M from $16.0M.","Company plans to initiate pivotal Phase 3 monotherapy trial of OP-1250 in second-line metastatic breast cancer in H2 2023.","Interim Phase 2 results of OP-1250 plus palbociclib to be presented at ESMO Breast Cancer on May 12, 2023.","Non-GAAP R&D expenses were $19.7M (excl. $3.1M SBC) vs $12.9M YoY; includes $2.8M restructuring charge."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008811","json":"https://secwatch.observer/filing/0001558370-23-008811.json","markdown":"https://secwatch.observer/filing/0001558370-23-008811.md","text":"https://secwatch.observer/filing/0001558370-23-008811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023008811/0001558370-23-008811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023008811/olma-20230509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:37:10.923573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15d367bde3d6a40c2f9885638a12e9b33482c1ab","claim":"Olema Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: net income $28.3 million.","evidence_excerpt":"Net loss for the quarter ended March 31, 2023, was $28.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023008811/0001558370-23-008811-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$28.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}